AstraZeneca Nexium NDA Includes "On-Demand" Dosing
Executive Summary
AstraZeneca's NDA for the Prilosec follow-on product Nexium includes an indication for "on demand" maintenance treatment for gastroesophageal reflux disease.
You may also be interested in...
AstraZeneca Nexium Labeling In Sweden Cites 93% GERD Healing At 8 Weeks
AstraZeneca's proton pump inhibitor Nexium demonstrates a 93% healing rate in erosive reflux esophagitis, according to Swedish labeling for the drug.
AstraZeneca Nexium Labeling In Sweden Cites 93% GERD Healing At 8 Weeks
AstraZeneca's proton pump inhibitor Nexium demonstrates a 93% healing rate in erosive reflux esophagitis, according to Swedish labeling for the drug.
Glaxo Zyban/Wellbutrin DTC Accounts Move To Grey Advertising
The award of Glaxo's bupropion franchise to Grey Advertising consolidates six of the firm's nine DTC-advertised products into one agency.